U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Xeroderma pigmentosum(XP)

MedGen UID:
21943
Concept ID:
C0043346
Congenital Abnormality
Synonyms: Xeroderma pigmentosa; XP
SNOMED CT: XP - Xeroderma pigmentosum (44600005); Xeroderma pigmentosum (44600005); Xeroderma of Kaposi (44600005); Melanosis lenticularis progressiva (44600005); Kaposi dermatosis (44600005); Pigmented epitheliomatosis (44600005); Atrophoderma pigmentosum (44600005); Angioma pigmentosum atrophicum (44600005)
Modes of inheritance:
Autosomal recessive inheritance
MedGen UID:
141025
Concept ID:
C0441748
Intellectual Product
Source: Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in individuals with two pathogenic alleles, either homozygotes (two copies of the same mutant allele) or compound heterozygotes (whereby each copy of a gene has a distinct mutant allele).
 
Gene (location): ERCC1 (19q13.32)
Related genes: XPC, XPA, POLH, ERCC5, ERCC4, ERCC3, ERCC2, DDB2
 
Monarch Initiative: MONDO:0019600
Orphanet: ORPHA910

Disease characteristics

Excerpted from the GeneReview: Xeroderma Pigmentosum
Xeroderma pigmentosum (XP) is characterized by: Acute sun sensitivity (severe sunburn with blistering, persistent erythema on minimal sun exposure) with marked freckle-like pigmentation of the face before age two years; Sunlight-induced ocular involvement (photophobia, severe keratitis, atrophy of the skin of the lids, ocular surface neoplasms); Greatly increased risk of sunlight-induced cutaneous neoplasms (basal cell carcinoma, squamous cell carcinoma, melanoma) within the first decade of life. Approximately 25% of affected individuals have neurologic manifestations (acquired microcephaly, diminished or absent deep tendon stretch reflexes, progressive sensorineural hearing loss, progressive cognitive impairment, and ataxia). The most common causes of death are skin cancer, neurologic degeneration, and internal cancer. The median age at death in persons with XP with neurodegeneration (29 years) was found to be younger than that in persons with XP without neurodegeneration (37 years). [from GeneReviews]
Authors:
Kenneth H Kraemer  |  John J DiGiovanna  |  Deborah Tamura   view full author information

Additional description

From MedlinePlus Genetics
Xeroderma pigmentosum, commonly known as XP, is an inherited condition characterized by an extreme sensitivity to ultraviolet radiation (UVR), which is present in sunlight and may also be found in some types of artificial lighting. This condition mostly affects the eyes and areas of skin exposed to the sun. Xeroderma pigmentosum is associated with an increased risk of UVR-induced cancers. People with this condition often experience premature aging. Some affected individuals also have problems involving the nervous system.

The signs of xeroderma pigmentosum usually appear in infancy or early childhood. About half of affected children develop a severe sunburn after spending just a few minutes in the sun. The sunburn causes redness and blistering that can last for weeks. However, some children with xeroderma pigmentosum can tan normally. 

By age 2, almost all children with xeroderma pigmentosum develop freckling of the skin in sun-exposed areas (such as the face, arms, and lips); this type of freckling rarely occurs in young children without the disorder. In affected individuals, exposure to sunlight often causes dry skin (xeroderma) and changes in skin coloring (pigmentation). This combination of features gives the condition its name.

People with xeroderma pigmentosum are 10,000 times more likely to develop non-melanoma skin cancer and up to 2,000 times more likely to  develop melanoma skin cancer compared to individuals without this condition. The types of skin cancer that can develop include basal cell carcinoma, squamous cell carcinoma, and melanoma. Most commonly, the first skin cancer appears in affected individuals before age 10. 

Researchers have identified at least eight genetic forms of xeroderma pigmentosum: complementation group A (XP-A) through complementation group G (XP-G), plus a variant type (XP-V). The types are distinguished by their genetic cause. All of the types increase the risk of skin cancer, although some are more likely than others to be associated with neurological abnormalities.

Without protection from the sun and other sources of UVR, most people with xeroderma pigmentosum develop multiple skin cancers during their lifetime. These cancers occur most often on  portions of the body that are exposed to the sun, including the face, the lips, the eyelids, the surface of the eyes, the scalp, and the tip of the tongue. Studies suggest that people with xeroderma pigmentosum may also have an increased risk of some internal cancers, including brain tumors, thyroid cancer, and blood cancers. Additionally, affected individuals who smoke cigarettes have a significantly increased risk of lung cancer.

The eyes of people with xeroderma pigmentosum may be painfully sensitive to UVR (photophobia). If the eyes are not protected from UVR, they may become bloodshot and irritated, and the clear front covering of the eyes (the cornea) may become cloudy. In some people, the eyelashes fall out and the eyelids may be thin and turn abnormally inward or outward. In addition to an increased risk of cancer on the surface of the eye, xeroderma pigmentosum is associated with noncancerous growths on the eye. Many of these eye abnormalities can impair vision.

About 30 percent of people with xeroderma pigmentosum develop progressive neurological abnormalities in addition to problems involving the skin and eyes. These abnormalities can include hearing loss, poor coordination, difficulty walking, movement problems, loss of intellectual function, difficulty swallowing and talking, and seizures. When these neurological problems occur, they tend to worsen with time.

Individuals with xeroderma pigmentosum may experience early menopause.  https://medlineplus.gov/genetics/condition/xeroderma-pigmentosum

Professional guidelines

PubMed

Moriwaki S, Kanda F, Hayashi M, Yamashita D, Sakai Y, Nishigori C; Xeroderma pigmentosum clinical practice guidelines revision committee
J Dermatol 2017 Oct;44(10):1087-1096. Epub 2017 Aug 3 doi: 10.1111/1346-8138.13907. PMID: 28771907
Salmon N, Tidman MJ
Practitioner 2016 Oct;260(1797):25-9. PMID: 29016090
Schubert S, Lehmann J, Kalfon L, Slor H, Falik-Zaccai TC, Emmert S
Eur J Hum Genet 2014 Jul;22(7) Epub 2013 Oct 9 doi: 10.1038/ejhg.2013.233. PMID: 24105368Free PMC Article

Suggested Reading

Recent clinical studies

Etiology

Krasikova YS, Lavrik OI, Rechkunova NI
Cells 2022 Nov 22;11(23) doi: 10.3390/cells11233723. PMID: 36496984Free PMC Article
Lehmann J, Seebode C, Martens MC, Emmert S
Anticancer Res 2018 Feb;38(2):1159-1164. doi: 10.21873/anticanres.12335. PMID: 29374753
Natale V, Raquer H
Orphanet J Rare Dis 2017 Apr 4;12(1):65. doi: 10.1186/s13023-017-0616-2. PMID: 28376890Free PMC Article
Lehmann AR, McGibbon D, Stefanini M
Orphanet J Rare Dis 2011 Nov 1;6:70. doi: 10.1186/1750-1172-6-70. PMID: 22044607Free PMC Article
Norgauer J, Idzko M, Panther E, Hellstern O, Herouy Y
Eur J Dermatol 2003 Jan-Feb;13(1):4-9. PMID: 12609773

Diagnosis

Lehmann J, Seebode C, Martens MC, Emmert S
Anticancer Res 2018 Feb;38(2):1159-1164. doi: 10.21873/anticanres.12335. PMID: 29374753
Natale V, Raquer H
Orphanet J Rare Dis 2017 Apr 4;12(1):65. doi: 10.1186/s13023-017-0616-2. PMID: 28376890Free PMC Article
Lehmann AR, McGibbon D, Stefanini M
Orphanet J Rare Dis 2011 Nov 1;6:70. doi: 10.1186/1750-1172-6-70. PMID: 22044607Free PMC Article
Webb S
BMJ 2008 Feb 23;336(7641):444-6. doi: 10.1136/bmj.39485.698356.AD. PMID: 18292171Free PMC Article
Norgauer J, Idzko M, Panther E, Hellstern O, Herouy Y
Eur J Dermatol 2003 Jan-Feb;13(1):4-9. PMID: 12609773

Therapy

Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK
Nat Med 2023 Nov;29(11):2825-2834. Epub 2023 Oct 2 doi: 10.1038/s41591-023-02568-1. PMID: 37783966Free PMC Article
Weon JL, Glass DA 2nd
Br J Dermatol 2019 Aug;181(2):249-255. Epub 2018 Nov 25 doi: 10.1111/bjd.17253. PMID: 30265743
Lehmann J, Seebode C, Martens MC, Emmert S
Anticancer Res 2018 Feb;38(2):1159-1164. doi: 10.21873/anticanres.12335. PMID: 29374753
Abdul-Wahab A, Qasim W, McGrath JA
Semin Cutan Med Surg 2014 Jun;33(2):83-90. doi: 10.12788/j.sder.0085. PMID: 25085667
Urabe K, Hori Y
Semin Cutan Med Surg 1997 Mar;16(1):81-5. doi: 10.1016/s1085-5629(97)80039-9. PMID: 9125769

Prognosis

Garcia-Moreno H, Langbehn DR, Abiona A, Garrood I, Fleszar Z, Manes MA, Morley AMS, Craythorne E, Mohammed S, Henshaw T, Turner S, Naik H, Bodi I, Sarkany RPE, Fassihi H, Lehmann AR, Giunti P
Brain 2023 Dec 1;146(12):5044-5059. doi: 10.1093/brain/awad266. PMID: 38040034Free PMC Article
Lehmann J, Seebode C, Martens MC, Emmert S
Anticancer Res 2018 Feb;38(2):1159-1164. doi: 10.21873/anticanres.12335. PMID: 29374753
Black JO
Head Neck Pathol 2016 Jun;10(2):139-44. Epub 2016 Mar 14 doi: 10.1007/s12105-016-0707-8. PMID: 26975629Free PMC Article
Lehmann AR, McGibbon D, Stefanini M
Orphanet J Rare Dis 2011 Nov 1;6:70. doi: 10.1186/1750-1172-6-70. PMID: 22044607Free PMC Article
Jen M, Murphy M, Grant-Kels JM
Clin Dermatol 2009 Nov-Dec;27(6):529-36. doi: 10.1016/j.clindermatol.2008.09.011. PMID: 19880040

Clinical prediction guides

Garcia-Moreno H, Langbehn DR, Abiona A, Garrood I, Fleszar Z, Manes MA, Morley AMS, Craythorne E, Mohammed S, Henshaw T, Turner S, Naik H, Bodi I, Sarkany RPE, Fassihi H, Lehmann AR, Giunti P
Brain 2023 Dec 1;146(12):5044-5059. doi: 10.1093/brain/awad266. PMID: 38040034Free PMC Article
Maguina M, Kang PB, Tsai AC, Pacak CA
Muscle Nerve 2023 Feb;67(2):101-110. Epub 2022 Oct 3 doi: 10.1002/mus.27721. PMID: 36190439Free PMC Article
Khatri ML
Int J Dermatol 2021 Mar;60(3):314-320. Epub 2021 Feb 4 doi: 10.1111/ijd.15395. PMID: 33538348
Jan SN, Khan FA, Khan BA
J Coll Physicians Surg Pak 2011 Feb;21(2):93-6. PMID: 21333240
Daya-Grosjean L
Adv Exp Med Biol 2008;637:19-27. doi: 10.1007/978-0-387-09599-8_3. PMID: 19181107

Recent systematic reviews

Hong DZ, Ong TCC, Timbadia DP, Tan HTA, Kwa ED, Chong WQ, Goh BC, Loh WS, Loh KS, Tan EC, Tay JK
Otolaryngol Head Neck Surg 2023 Jun;168(6):1324-1337. Epub 2023 Feb 17 doi: 10.1002/ohn.222. PMID: 36802061
Brambullo T, Colonna MR, Vindigni V, Piaserico S, Masciopinto G, Galeano M, Costa AL, Bassetto F
Biomed Res Int 2022;2022:8549532. Epub 2022 Jul 18 doi: 10.1155/2022/8549532. PMID: 35898688Free PMC Article
de Andrade FAG, Cavalcanti CEO, Isoldi FC, Ferreira LM
Indian J Dermatol Venereol Leprol 2021 Mar-Apr;87(2):176-189. doi: 10.25259/IJDVL_431_19. PMID: 33769755
Zhang W, Zhang Z
Oncotarget 2016 Dec 27;7(52):86621-86629. doi: 10.18632/oncotarget.13361. PMID: 27863412Free PMC Article
Green AC, McBride P
BMJ Clin Evid 2014 Aug 18;2014 PMID: 25137222Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...